What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?

Program Goals

Program Overview

Intensifying Diabetes Therapy In Patients Already On Basal Insulin: Challenge

"Maximum" Dose of Basal Insulin

Combination Injectable Therapy: Evidence-Based Recommendations

Time From Initiation of Basal Insulin to Intensification in Clinically Eligible Patients*

Treatment for Hyperglycemia Changes Over Time in Patients With T2DM

"Maximum" Dose of Basal Insulin (cont)

Achieving Glycemic Control

Relative Contributions of FPG and PPG to HbA1c

Basal Insulin/GLP-1 RA FRC Agents

LixiLan-L Trial: Key Results

DUAL V: Key Results

CVOTs With GLP-1 RAs

Mechanism of Action of GLP-1 RAs

Nutrition Therapy in Patients With T2DM

Benefits of Adding a GLP-1 RA to Basal Insulin vs Adding Prandial Insulin

Cost-Effectiveness of FRC Therapy: Data From DUAL V

Integrating Basal Insulin/GLP-1 RA FRC Therapy Into Primary Care: Challenges

Basal Insulin/GLP-1 RA FRC Agents

Integrating Basal Insulin/GLP-1 RA FRC Therapy Into Primary Care: Challenges (cont)

Mean Daily Dose of Basal Insulin Significantly Lower With FRC Therapy

Fewer Adverse GI Events With FRC Agents vs GLP-1 RAs

Basal Insulin/GLP-1 RA FRC Agents: Available in Prefilled Pens

Minimizing the Risk of Nausea When Adding a GLP-1 RA to Basal Insulin

Understanding the Role of Basal Insulin/GLP-1 RA FRC Agents In T2DM Management

Using Basal Insulin/GLP-1 RA FRC Therapy in Clinical Practice -- IDegLira

Using Basal Insulin/GLP-1 RA FRC Therapy in Clinical Practice -- IGlarLixi

Switching to Basal Insulin/GLP-1 RA FRC Therapy: Practical Considerations

Switching to Basal Insulin/GLP-1 RA FRC Therapy: Practical Considerations (cont)

IGlarLixi: Method of Administration

Insulin Dose

Basal Insulin/GLP-1 RA FRC Therapy: Future Considerations

Summary

Abbreviations